Drugs / Methimazole
Methimazole
also known as
MMI · Thiamazol · Favistan · Mercaptizole · NSC-38608 · tapazole · Thiamazole · Tiamazol
Small molecule targets TPO via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TAPAZOLE | — | 1950-06-21 | fda.gov ↗ |
Trials 10
194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05017610 | Oct 2021 → Oct 2022 | gliosarcoma | Emory University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT04346901 | Aug 2019 → Jan 2020 | hyperpigmentation of the skin, hyperthyroidism | Indonesia University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05607407 | Jan 2023 → Sep 2026 overdue | glioblastoma | Case Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT02654041 | Mar 2016 → Jun 2017 | glioblastoma | Musli Thyropeutics Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT00001421 | Jun 1995 → Apr 2001 | dermatomyositis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04776993 | Mar 2023 → Sep 2024 | disease of orbital part of eye adnexa | University of Pisa | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01849861 | Sep 2011 → Jul 2014 | — | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 4 | NCT00150137 | Jan 2003 → Dec 2004 | Graves disease, toxic multinodular goitre | Odense University Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07857421 | Oct 2026 → Jun 2027 expected | Graves disease, thyrotoxicosis | THYROSCOPE INC. | Not yet recruiting | No outcome recorded |
| — | NCT02727738 | Jan 2014 → Sep 2015 | Graves disease | University of Pisa | Completed | No outcome recorded |
| Comparator or background therapy13 trials | ||||||
| Phase 1/2 | NCT00150111 Background | Jun 2003 → Oct 2006 | Graves disease, endocrine exophthalmos | Odense University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06240455 Background | Mar 2026 → Mar 2029 | Graves disease | Worg Biotherapeutics Inc. | Suspended | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT07369063 Background | Aug 2025 → Feb 2027 expected | Graves disease | Northwell Health | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06068179 Background | Oct 2023 → Oct 2025 overdue | Graves disease | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05118542 Comparator | Jan 2019 → Jun 2020 | Graves disease, atherosclerosis | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT03066076 Comparator | Mar 2017 → Feb 2019 | Graves disease, endocrine exophthalmos | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT05461820 Comparator | May 2018 → Dec 2023 overdue | Graves disease | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT01458600 Background | Sep 2006 → Feb 2016 | Graves disease | Mikael Lantz | Completed | No outcome recorded |
| Phase 4 | NCT00917241 Background | Jun 2004 → Dec 2008 | Graves disease | Xiao-Ming Mao | Completed | Met primary |
| Phase 4 | NCT00150124 Comparator | Jan 2003 → Dec 2008 | Graves disease, toxic multinodular goitre | Steen Bonnema | Completed | No outcome recorded |
| — | NCT06540469 Background | Aug 2024 → Jul 2027 expected | Graves disease | Shandong Provincial Hospital | Not yet recruiting | No outcome recorded |
| — | NCT01560299 Comparator | Feb 2010 → Jan 2012 | Graves disease | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01893450 Comparator | Jun 2008 → Jun 2013 | disease of orbital part of eye adnexa | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-29 | Upsher-Smith Laboratories | Upsher-Smith Launches Methimazole Tablets, USP upsher-smith.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Methimazole | “After 6 months of treatment with methimazole (MMI), the patients were randomly assigned to receive either MMI (96 patients) alone or MMI combined with IID (MMI+IID; 95...” PMID 19850691 ↗ Oct 2009 |
| Known as | Favistan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1515 ↗ |
| Known as | Mercaptizole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1515 ↗ |
| Known as | MMI | “Anti-thyroid drugs (ATDs), such as propylthiouracil (PTU) and methimazole (MMI), are commonly used for GD treatment, and studies have suggested a link between these drugs and...” PMID 39355401 ↗ Jun 20246“After 6 months of treatment with methimazole (MMI), the patients were randomly assigned to receive either MMI (96 patients) alone or MMI combined with IID (MMI+IID; 95...” PMID 19850691 ↗ Oct 2009 “This open label pilot study will assess the (1) activity of methimazole (MMI), a down-regulator of MHC Class I transcription used in treatment of autoimmune thyroiditis (AIT)” NCT00001421 ↗ “All patients are rendered euthyroid by methimazole (MMI) and randomized either to stop MMI eight days before 131I or to be set on BRT.” NCT00150124 ↗ “Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug.” PMID 32929476 ↗ Dec 2020 “Graves' disease is the most common cause of hyperthyroidism and is usually treated with antithyroid drugs such as methimazole (MMI).” NCT07857421 ↗ “Individualized methimazole (MMI)” NCT06540469 ↗ |
| Known as | NSC-38608 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1515 ↗ |
| Known as | tapazole | “methimazole,tapazole;dexamethasone,hexadecadrol” NCT00917241 ↗ |
| Known as | Thiamazol | “Thiamazol, Propylthiouracil” NCT03066076 ↗ |
| Known as | Thiamazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1515 ↗ |
| Known as | Tiamazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1515 ↗ |
| Action | Inhibit | “a down-regulator of MHC Class I transcription” NCT00001421 ↗1“Thyroid peroxidase inhibitor” CHEMBL1515 ↗ |
| Modality | Small molecule | — CHEMBL1515 ↗ |
| Route | Oral | “MMI will be administered orally at 30 mg twice a day for six months.” NCT00001421 ↗ |
| Target | TPO | “Thyroid peroxidase inhibitor” CHEMBL1515 ↗ |